Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

More documents

Recommendations

Info

10 Appendix Identification midazolam [ug/L] α-hy-midazolam [ug/L] 4-hy-midazolam [ug/L] Identification midazolam [ug/L] α-hy-midazolam [ug/L] 4-hy-midazolam [ug/L] 13-V2-t0 nn nn nn 13-V3-t0 nn nn nn 13-V2-t1 19.4 nn nn 13-V3-t1 nn nn nn 13-V2-t2 64 nn nn 13-V3-t2 10.8 nn nn 13-V2-t3 34.3
10 Appendix Identification midazolam [ug/L] α-hy-midazolam [ug/L] 4-hy-midazolam [ug/L] Identification midazolam [ug/L] α-hy-midazolam [ug/L] 4-hy-midazolam [ug/L] 14-V2-t0 nn nn nn 14-V3-t0 nn nn nn 14-V2-t1 49.9 nn nn 14-V3-t1 nn nn nn 14-V2-t2 47.9 nn nn 14-V3-t2 2.7 nn nn 14-V2-t3 26.1 0.3 nn 14-V3-t3 12.4 nn nn 14-V2-t4 25.6 1.3
Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
Page 5 and 6:
Acknowledgments At the Hospital Pha
Page 7:
Index EXPERIMENTAL SECTION 5 Projec
Page 11 and 12:
Summary Summary Transmucosal nasal
Page 13:
Summary Project III: In this random
Page 17:
THEORETICAL SECTION
Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
Page 25 and 26:
2. Impact of anatomy and physiology
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
Page 33 and 34:
3. Midazolam 3.2.1 Indications and
Page 35 and 36:
3. Midazolam Administration of high
Page 37 and 38:
3. Midazolam gastrointestinal tract
Page 39 and 40:
4. Compounding of nasal midazolam p
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49:
Page 53 and 54:
5. Project I: Development of prepar
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67:
Page 70 and 71:
6. Project II: Pharmacokinetic of t
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
7. Project III: Transmucosal nasal
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103:
Page 106 and 107:
8 Overall discussion pharmacokineti
Page 108 and 109:
8 Overall discussion considered as
Page 111:
Appendix
Page 114 and 115:
10 Appendix 10.2 Project I 10.2.1 R
Page 116 and 117: 10 Appendix 10.2.4 Specification: M
Page 118 and 119: 10 Appendix 10.2.6 Specification: C
Page 120 and 121: 10 Appendix Katja Suter-Zimmermann
Page 122 and 123: 10 Appendix 10.2.9 Specification: C
Page 150 and 151: 10 Appendix 10.3.2 Case report form
Page 158 and 159: 10 Appendix Frequency 10.3.5 Intens
Page 160 and 161: 10 Appendix 10.3.7 Serumconcentrati
Page 162 and 163: 10 Appendix Identification midazola
Page 164 and 165: 10 Appendix Identification midazola
Page 168 and 169: 10 Appendix 10.3.8 Midazolam serum
Page 170 and 171: 10 Appendix 10.3.10 Nasal delivery
Page 174 and 175: 10 Appendix 10.4.3 Flowchart: multi
Page 185 and 186: 11 References 11 References Abrams,
Page 187 and 188: 11 References Erjefalt, J.S., I. Er
Page 189 and 190: 11 References Irie, T. and K. Uekam
Page 191 and 192: 11 References Malinovsky, J.M., C.
Page 193 and 194: 11 References Scheepers, M., B. Sch
Page 195 and 196: 12 Curriculum vitae 12 Curriculum v
show all

Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

Create successful ePaper yourself

Delete template?

Save as template?